^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AMG 794

    i
    Other names: AMG 794, AMG794, AMG-794
    Company:
    Amgen
    Drug class:
    CD3 agonist, CLDN6 inhibitor
    Related drugs:
    7ms
    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=98, Recruiting, Amgen | Active, not recruiting --> Recruiting | Trial completion date: Jun 2027 --> Feb 2028 | Trial primary completion date: Dec 2025 --> Apr 2026
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    12ms
    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=98, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    1year
    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=98, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    over1year
    A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=98, Not yet recruiting, Amgen | Trial completion date: Nov 2027 --> Feb 2027 | Trial primary completion date: May 2026 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    over1year
    A Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
    P1, N=98, Not yet recruiting, Amgen | Trial completion date: Jun 2027 --> Nov 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    almost2years
    A Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer. (clinicaltrials.gov)
    P1, N=98, Not yet recruiting, Amgen | Trial completion date: May 2026 --> Jun 2027 | Initiation date: May 2022 --> Oct 2022 | Trial primary completion date: Jul 2024 --> Dec 2025
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794
    2years
    A Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer. (clinicaltrials.gov)
    P1, N=98, Not yet recruiting, Amgen
    New P1 trial
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 expression
    |
    AMG 794